Filana Therapeutics, Inc.
Filana Therapeutics, Inc. (Nasdaq: FLNA) is a clinical-stage biotechnology company developing treatments for central nervous system disorders, with a current focus on Tuberous Sclerosis Complex-related epilepsy and diseases associated with filamin A dysregulation or overexpression. Its lead candidate, simufilam, is an… From the company’s description.
In fiscal 2025, Filana Therapeutics, Inc. reported a net loss of $90.97M. Operations used $32.25M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Filana Therapeutics, Inc. does
In the company’s own words
Filana Therapeutics, Inc. (Nasdaq: FLNA) is a clinical-stage biotechnology company developing treatments for central nervous system disorders, with a current focus on Tuberous Sclerosis Complex-related epilepsy and diseases associated with filamin A dysregulation or overexpression. Its lead candidate, simufilam, is an oral small molecule designed to modulate filamin A; the company is pursuing its development for TSC-related epilepsy and exploring other potential indications. A planned proof-of-concept clinical trial in TSC-related epilepsy is subject to an FDA clinical hold. The company discontinued its Alzheimer’s disease development program in 2025 after ending its Phase 3 studies of simufilam, and discontinued development of its early-stage blood-based Alzheimer’s detection program, SavaDx. It has no reportable business segments described in the provided business information. The company outsources preclinical and clinical studies, formulation, and manufacturing, and relies on Evonik for clinical-grade simufilam drug substance. Research and development expense was $26.6 million in fiscal 2025. Its website is www.filanatx.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- AUSTIN, TX
- Fiscal year end
- December
- CIK
- 1069530
- SIC
- 2834
Financial performance, year by year
Fiscal 2011–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Filana Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Filana Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Filana Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Filana Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Filana Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”